A Case-based Approach to Treating Diabetes. D.C. Dugdale MD University of Washington Dawn DeWitt MD University of Melbourne
|
|
- Shanon Marshall
- 6 years ago
- Views:
Transcription
1 A Case-based Approach to Treating Diabetes D.C. Dugdale MD University of Washington Dawn DeWitt MD University of Melbourne
2 Conflicts of Interest Neither Dr. DeWitt nor Dr. Dugdale do paid lectureships or accept gifts from the pharmaceutical industry. Parts of this talk and a scientific review were published in JAMA 2003;289: and
3 Overview Use of and complications related to newer oral agents Use of new insulin regimens Use of insulin pump Treating steroid-induced hyperglycemia 3-Day glucose sensors Real Life
4 Case 1 A 58 y.o. man presented for care in 1994 on glyburide 2.5 mg BID with an A1C of 7.8%. Over the subsequent 6 years, his glyburide was increased to 10 mg BID. In 2000 his A1C was 10%. He had no known complications or comorbidities. Weight 161 lbs. BMI 24.
5 Case 1 treatment issues Augmenting oral therapy is unlikely to achieve goals Oral agents lower A1c 1-2% or 3% in combination Thus patients with an A1c > 9 will not reach target More pills may be toxic and expensive However, patients are often reluctant or refuse to take insulin If patients are willing to take insulin: bedtime NPH or glargine are preferred
6 UKPDS Extrapolated ß-cell Function 100 IGT PPH T2 ß -Cell Function (% ß) Years UKPDS Lancet 1997, Lebovitz, 1999.
7 Case 1-cost comparison Current regimen: metformin was added and glyburide was decreased glyburide 5 mg bid + metformin 1000 mg bid tests 1/day cost/month ~ $67 for pills, $22 for 1 test/day Proposed starting regimen insulin glargine 15 Units/day (0.2 Units/kg) tests 2/day cost/month ~$56 for insulin + syringes, $44 for 2 tests/day Pill cost/month: glyburide ~$15; metformin ~$52; repaglinide ~$95; rosiglitazone (Avandia) ~$136
8 Take Home Messages B-cell function is < 50%, and often at 10-20%, at presentation in many patients with T2DM Once A1C is >9%, additional oral agents are unlikely to adequately control glucose Insulin at bedtime with or without oral agents is the preferred strategy, especially if B-cell function is relatively preserved Cost is heavily dependent on testing frequency, but insulin is often less expensive than multiple oral medications
9 Case 2 A 54 year-old woman with type 2 diabetes treated with glyburide and rosiglitazone presents with an asthma attack. She has gained 30 lbs since her visit 3 months ago; BMI 35. Exam reveals wheezing and basilar crackles, elevated JVP, an S3, and edema. She has no cardiac history and is ruled out for an MI.
10 Thiazolidinediones and CHF Increase peripheral/muscle uptake of glucose mean 4-8 kg gain; kg is possible Adipose tissue and fluid retention Increasing recognition of CHF requiring hospitalization precipitated by TZDs Delea, 2002
11 Take home messages Safe use of TZDs Use with insulin risks large weight gain, only pioglitazone FDA approved in combination Not recommended in NYHA III-IV CHF Use caution in NYHA I-II CHF Liver monitoring: before initiation and every 2 months x 12 months; monitor closely if >1.5x ULN; stop if > 3x ULN or jaundice
12 Case 3 A 68 year-old woman with T2DM and CHF has been on 70/30 (N/R) insulin for 4 years. She takes 16 Units in the morning and 12 Units in the evening. Her diet is high in rice and carbohydrates. FBG runs and she has hypoglycemic events if her lunch is late. Her pre-dinner BG runs Her A1C is 8.5%
13 Non-physiologic Insulin Replacement JAMA. 2003;289: American Medical Association
14 Insulin options NPH/Regular or UL/Regular Premeal and nocturnal hypoglycemia common 70N/30R pre-mixed Same as above; convenient 75/25 pre-mixed protamine lispro/lispro 70/30 pre-mixed protamine aspart/aspart May be better convenience insulins, may need supplemental insulin at lunch Good for patients with high carbohydrate diets or premeal (e.g., lunch or dinner) hypoglycemia Basal-prandial combinations, insulin glargine, or CSII
15 Premix intermediate/rapid insulin JAMA. 2003;289: American Medical Association
16 Case 4 A 76 y.o. woman with T2DM and recent nephropathy (Cr 1.6) is on 70/30 (NPH/R) BID with an A1c between 7.2% and 8.6%. She is very intelligent and values independence and flexibility. She prefers to get up after 10 a.m. some days and her meal schedule is very erratic, but usually she eats an early dinner. She frequently becomes hypoglycemic in the evening.
17 Insulin Stacking JAMA. 2003;289: American Medical Association
18 Basal-Prandial Insulin JAMA. 2003;289: American Medical Association
19 Why use glargine? Glargine has a 24-hour duration without peak Clear, must be given separately Better basal insulin than NPH, which has a hour duration with a peak Lower FPG and better post-dinner control Equivalent daytime control 25% less hypoglycemia at night Less weight gain (1 kg less at 28 weeks) Significantly higher patient satisfaction and convenience Witthaus, Diabet Med, 2001.Rosenstock, Diabetes Care, Rosenstock, Diabetes Care, 2000.
20 Using bedtime insulin Give at 9 PM ( bedtime ); check FBG Increase by 2 Units every 3 days if FBG > 110 mg/dl Many T2DM patients need large doses Overlap when switching to glargine in T1 because of lag to onset of action (4-5 hours)
21 NPH vs. Glargine The 4002 Trial Randomized open-label parallel trial x 24 weeks in 756 overweight T2DM patients with A1C > 7.5% 1 or 2 oral agents Bedtime NPH vs Glargine 60% attained A1C < 7% 25% fewer patients on glargine had nocturnal hypoglycemia (33% vs 26%) Symptomatic hypoglycemia was 21-48% lower with glargine» Riddle, Diabetes Care, 2003;26:
22 Diabetes 4002 Trial Protocol If CBG is above target for 3 consecutive days, increase insulin glargine as follows: >139 mg/dl increase glargine 4-6 units mg/dl increase glargine 2-4 units mg/dl increase glargine by 2 units < 99 mg/dl no change If CBG < 63 mg/dl on more than one occasion decrease dose by 2 units Riddle, Diabetes Care, 2003;26:
23 Prandial therapy: why and how Better post-prandial control with decreased glucose excursions and less late hypoglycemia Insulin lispro or aspart are convenient Meal-time injection: onset 15 minutes, peak minutes, duration 3-5 hours Adaptation to meal content and CBG Carbohydrate counting: 1 Unit/10-15 gm carb Use additional supplement based on premeal glucose (1-2 Unit/50 mg/dl over 150 mg/dl)
24 Prandial therapy: carbohydrate counting Carbohydrate counting: two techniques: count grams of carbohydrate from label or portion size and calculate insulin using a ratio, OR, plan portion sizes around carbs, the term used for each 15 gram increment of carbohydrate Most basic physiologic insulin regimens call for a dose or supplement of 1-2 units per carb Involve diabetes educator for patient training
25 Prandial therapy: carb counting, cont d Carbohydrate counting examples (each are 15 g): Apple, ¾ medium Apple juice, ½ cup Bagel, ¼ (e.g., half of a half) Bread, sandwich, 2/3 slice Cereal, ½ - ¾ cup French fries, 1/3 of a small bag (depends on store) Hamburger, ½ (including bun) Milk, 10 ounces Orange juice, ½ cup Pasta, cooked, ½ cup Rice, cooked, 1/3 cup Free foods: most vegetables, most nuts, cheese, most meats or fish
26 Starting basal-prandial insulin Major considerations: weight and insulin resistance; e.g. use more in type 2 Traditionally: 2/3 long-acting and 1/3 short-acting Basal-prandial regimens=½ basal and ½ prandial Usual starting dose for basal component is Units/kg (physiologic regimens) In a patient already on NPH/UL use ~80% of NPH/UL dose as glargine For prandial insulin use carb counting or diet history with % of carbohydrates at each meal as a guide
27 Take home messages The concept of basal-prandial physiologic insulin dosing often helps improve patients understanding Prandial rapid-acting insulins cause less hypoglycemia than regular insulin Bedtime NPH or Glargine Bedtime dosing gives better control of FBG and easier dose adjustment Glargine: less weight gain and 25% less hypoglycemia with glargine vs NPH Glargine is $47/vial vs NPH $28/vial
28 Case 5 58 y/o man, type 2 DM, HbA1c 7.5% 400 Glucose Concentration (mg/dl) N, 10R 6N, 12H :00 AM 4:00 AM 8:00 AM 12:00 PM 4:00 PM 8:00 PM 12:00 AM
29 Take home messages 3-Day Glucose Sensors Indications: Uncontrolled diabetes Life-threatening hypoglycemia Need to educate patient Current cost at UW is $400 Equivalent data from frequent CBGs possible But hard to obtain representative data and highest incidence of severe hypoglycemia at night Common finding is unexpectedly large glucose excursions
30 Case 6 A 32 year-old man with type 1 DM presents with severe throat pain, unable to eat. He uses an insulin pump, basal rate 1 Unit/hour lispro. He uses 1 Unit lispro per 10 gm of carbohydrate for meals. Initially he is NPO. How should he be managed? After 36 hours, EGD shows HSV esophagitis. Acyclovir and TPN are started. How would you manage him now?
31 Take home messages Pumps in the hospital Probably the easiest way to manage patients Use only basal rates for fasting patients Adjust based on usual CBG monitoring Factors that affect insulin needs for inpatients Insulin resistance from endogenous stress hormones or medications (steroids) Often more caloric control with meals Decreased physical activity Give lispro supplements with intake (using pump!)
32 Case 7 A 62 y.o. woman with T2DM managed with metformin and glyburide presents with altered mental status. Glucose is 40 mg/dl; Cr is 5.0 (baseline 1.2 mg/dl). Glucose infusion was begun. She required 10 Units NPH and 10 Units regular SC BID. Renal biopsy showed interstitial nephritis and methylprednisolone was begun. Two hours later her CBG was 500 mg/dl. A supplemental scale was used for the next 24 hours with fingersticks remaining at 500 mg/dl despite 60 Units regular insulin SC.
33 Issues in patients on steroids In the hospital, insulin drip may be best Physiologic effects of steroids Increased gluconeogenesis Suppress insulin secretion Decreased peripheral uptake Increased insulin resistance (esp. with wt gain) Often normal FBG but high post-prandial glucose measurements Consider prandial insulin, repaglinide (limited)
34 Real life issues Basal prandial insulin strategy and carbohydrate counting give maximum flexibility Self monitoring enhances the patient s understanding and sense of control over diabetes Treatment plans evolve at different rates Total insulin dose goal higher than often realized 1 unit per kg for type 1 (after honeymoon phase) units often needed for bedtime basal insulin for T2
35 Hospitalized patients Myths of diabetes care Just use a sliding scale. Sliding scale attempts to retrospectively lower elevated BG levels by giving predetermined insulin doses on a predetermined schedule Does not consider patient s prehospital regimen Does not consider meal time or status, or differing target BG based on time relative to meals
36 Hospitalized patients Myths of diabetes care Just use a sliding scale. Associated with cycles of hypo- and hyperglycemia Clinical trials find either no benefit or worse control Ann Fam Med 2003;1: Arch Int Med 1997;157:
37 Hospitalized patients Myths of diabetes care No food, no insulin. Patients with type 1 always need insulin. DKA is an insulin deficiency state, not merely a high glucose state Many patients with type 2 diabetes need insulin to maintain metabolic control
38 Hospitalized patients Myths of diabetes care Just keep their glucose under 400. In general medical and surgical patients, adverse outcomes associated with fasting BG > 126 mg/dl or random BG > 198 mg/dl Umpierrez, J Clin Endo Metab 2002;87:
39 Morbidity/Mortality and Hyperglycemia in Inpatients Hyperglycemia present in 38% of admissions 26% known DM, 12% had no history of diabetes Normoglycemia Known DM New hyperglycemia Length of Stay 4.5 days 5.5 days 9 days Risk of death due to infection 4% 4% 12% In hospital mortality 1.7% 3% 16% Umpierrez, J Clin Endo Metab 2002;87:
40 Better glucose control results in: Shorter stays Fewer surgical wound infections Fewer infectious complications in medical patients Better outcomes patients with MI (DIGAMI) Better outcomes in patients with stroke Reduced mortality in SICU patients on insulin drips with glucose < 110 mg/dl» Umpierrez, J Clin Endoc Metab, Capes, Lancet, Capes, Stroke, Latham, Infection Cont and Hosp Epi, Zerr, Ann Thor Surg, Malmberg, J Am Coll Cardio, Van der Berghe, NEJM, 2001.
41 Practical application Keeping the glucose below the renal threshold (~180 mg/dl) simplifies fluid and electrolyte management Recommended goal for CBG is mg/dl Consider insulin glargine or IV insulin with pre-meal rapid-acting supplements Preprinted order sheet simplifies care. UW protocol published: Trence, et al. J Clin Endo Metab 2003:88(6):2430.
42 Subcutaneous Insulin Orders: Blood Glucose (BG) Monitoring: Before meals and at bedtime. hrs after meals. 2-3 am Prandial Insulin Orders Breakfast Lunch Dinner Bedtime Give units of: Lispro (Humalog ) Aspart (Novolog ) U-100 Regular Give units of: Lispro (Humalog ) Aspart (Novolog ) U-100 Regular Give units of: Lispro (Humalog ) Aspart (Novolog ) U-100 Regular Basal Insulin Orders Give units of: NPH Lente Ultralente Glargine Give units of: NPH Lente Ultralente Glargine Give units of: NPH Lente Ultralente Glargine Give units of: NPH Lente Ultralente Glargine
43 Premeal algorithm for Hyperglycemia: To be administered in addition to scheduled insulin dose to correct premeal hyperglycemia. Lispro Aspart Low Dose Algorithm (for patients requiring 40 units of insulin per day) Premeal Blood Glucose Additional Insulin unit units units units >349 5 units
44 I wonder what they think Your feedback is important to us! Please remember to fill out and return your Evaluations
45 Cost of oral agents Glipizide 10 mg, #60 $10.99 Glucotrol XL (glipizide) 10 mg, #60 $51.98 Metformin 1000 mg, #60 $55.99 Glucophage 500 mg, #120 $93.98 Metformin 24 hr tab 500 mg, #120 $79.98 Avandia (rosiglitazone) 8 mg, #30 $ Precose (acarbose) 100 mg, #90 $72.07 Prandin (repaglinide) 2 mg, #90 $95.42 Generic glipizide and glyburide ~ same cost Drugstore.com prices
46 Cost of insulin 100 Units/ml, 10 ml Humulin 70/30 $29.52 Humulin N $28.42 Humulin R $28.42 Humulin U $28.42 Lantus (glargine) $46.99 Humalog (lispro) $55.99 Humalog 75/25 $61.84 Insulin should be discarded after one month Drugstore.com prices
47 Cost of supplies Accu-chek Advantage monitoring kit $73.99 Accu-chek test strips, #100 $72.99 B-D Ultra-fine II short 30G 1cc, #100 $28.66 Insulin pens Insulin pump Pump supplies (tubing/infusion sets) free but increase cost of insulin ~30% ~$5000 ~$1500/yr Drugstore.com prices
48 American Diabetes Association: Clinical Practice Recommendations ADA practice guidelines available as full text at or via ADA website Includes guidelines for treatment of type 1 and type 2 diabetes, as well as multiple practical topics
49 Insulin Pearls on the ADA website Don t mix glargine with other products When mixing rapid insulin and intermediate insulin, inject within 15 minutes Syringe reuse acceptable with meticulous cleanliness; small needles (30 ga) develop barbed tips easily Insulin pens improve dose accuracy Injection site should be clean, alcohol wipe unnecessary Injection site rotation reduces lipoatrophy but increases variability of absorption fastest: abdomen > arm > leg exercise increases rate of absorption
50 Insulin Infusion Protocol General Surgical patients who have received an oral diabetes medication within 24 hrs should start when CBG > 120. Other patients start when BG > 70. Discontinue insulin infusion when a patient is eating and has received first dose of subcutaneous insulin. Choosing an algorithm Algorithm 1: Start here for most patients. Algorithm 2: If algorithm fails, S/P CABG, S/P transplant, or glucocorticoids or in patient on > 80U insulin/day as outpatient Algorithm 3 or 4: No patients start here. Use for failure of #1 or 2 Changing algorithms Moving up: Algorithm failure if CBG > 180 mg/dl, and the CBG does not change by at least 60 mg/dl in 1 hour. Moving down: When CBG is less than 70 mg/dl x 2 hours
51 UWMC Insulin Drip Protocol Algorithm 1 Algorithm 2 Algorithm 3 Algorithm 4 BG Units / hr BG Units / hr BG Units / hr BG Units / hr <60 = Hypoglycemia (See below for treatment) <70 Off <70 Off <70 Off <70 Off
52 Prandial therapy: carb counting, cont d Sources of information for patients General reference: Reference for fast foods:
53 Annotated Bibliography Papers of interest to generalists
54 DeWitt DE, Dugdale DC. Clinical Correlations: Using New Insulin Strategies in the Outpatient Treatment of Diabetes. JAMA, May 7, Contains more detailed discussion of principles discussed in this workshop Accompanying scientific review: DeWitt DE, Hirsch IB. Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes: Scientific Review.
55 ADA Guidelines: Implications of the Diabetes Control and Complications Trial. Diabetes Care 2003;26:S25- S27. Also at and UpToDate 11.1 Compared intensive therapy (pump or 3+ daily injections) to conventional therapy (1-2 daily injections) in T1DM. Intensive group mean A1c of 7.2%, mean glu 155 mg/dl; conventional group mean A1c 9.0%. In primary prevention cohort, 6 yr. mean follow-up: retinopathy risk 76%, microalbuminuria risk 34%, neuropathy risk 69%. In secondary prevention cohort, 6 yr. mean follow-up, retinopathy risk 54%, microalbuminuria risk 43%, neuropathy risk 57%. Intensive insulin therapy slows decline of B cell function (Ann Intern Med 1998;128: )
56 ADA Guidelines: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003;26:S28-S32. Also at and UpToDate Study Design RCT new onset T2 DM; randomized to sulfonylurea, metformin, or insulin, with different glucose goals. Conventional Rx goal: fasting glu <270 mg/dl and no sx. Intensive Rx goal: fasting glu <108 mg/dl; premeal glu <126 mg/dl. Insulin regimens: q day NPH or UL, with premeal R added if more than 14 U per day of basal insulin used, OR premeal or bedtime glu <126 mg/dl.
57 ADA Guidelines: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003;26:S28-S32. Also at and UpToDate Original reports: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 DM. Lancet 1998;352: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 DM. Lancet 1998;352:
58 ADA Guidelines: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003;26:S28-S32. Also at and UpToDate Conclusions. Baseline median A1c 9.1%; conventional Rx group achieved median A1c 7.9%, intensive Rx group 7.0%. Risk of microvascular complications continuously related to glucose control as assessed by HBA1c. For every 1% decrease in A1c, there was 35% reduction of complication risk, with no threshold level.
59 ADA Guidelines: Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 2003;26:S28-S32. Also at and UpToDate Conclusions Risk of cardiovascular complications continuously related to glucose control as assessed by HBA1c. For every 1% decrease in A1c, there was 25% reduction in diabetes-related deaths, 7% reduction in all-cause mortality, and 18% reduction in MI, again with no threshold level In subgroup of obese patients (ideal body weight >120%; corresponds to BMI >26), metformin used in the intensive treatment group showed 42% reduction in diabetes-related deaths, 36% reduction in allcause mortality, and 39% reduction in MI compared to conventional group; SU and insulin arms had no benefit on these endpoints.
60 Wright et al. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UKPDS. Diabetes Care 2002;25: Design Substudy of UKPDS in which patients who were in intensive therapy group with sulfonylurea had ultralente insulin added if fasting plasma glucose (FPG) > 6 mmol/l (to convert mmol/l to mg/dl, multiply by 18). Initial dose was 2 x (fasting plasma glu [mmol/l] - 3), for a person at 100% ideal body weight (IBW). For each 20% above IBW, initial dose was increased by 50% of the dose for 100% IBW. Regular insulin was added for premeal glu > 126 mg/dl. Comparison group was that who received insulin only.
61 Wright et al. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UKPDS. Diabetes Care 2002;25: Results. Over 6 yrs, 53% had insulin added Median HBA1c 6.6% in combination group, 7.1% in insulin only group Of combination group, 47% had HBA1c < 7%; 35% in insulin only group Annual rate of major hypoglycemia 1.6% in combination group, 3.2% in insulin only group
62 Malmberg et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): Effects on mortality at one year. J Am Coll Card 1995;26: patients with diabetes and acute MI. 306 randomized to insulin-glucose infusion followed by multiple injection insulin therapy (MIT) for > 3 mos Vs. 314 conventional treatment. 1-year mortality 18.6% mortality in infusion group Vs. 26.1% in the control group. ARR 7.5%; RRR 29%. Conclusion: Insulin-glucose infusion and MIT improves 1 year mortality in patients with diabetes (this was particularly notable in low risk patients who had not previously been treated with insulin).
63 Inzucchi. Oral antihyperglycemic therapy for type 2 diabetes, scientific review. JAMA 2002;287: Companion article, Holmboe ES. Oral antihyperglycemic therapy for type 2 diabetes, clinical applications. JAMA 2002;287: , contains illustrative cases. Compared with placebo, monotherapy lowers A1C levels 1-2%; combination therapy lowers them 2-3%. Sulfonylureas decrease microvascular risk Metformin decreases microvascular and macrovascular risk Thazolidinediones not proven to reduce vascular risk Alpha glucosidase inhibitors target postprandial glycemia and are nonsystemic Non-sulfonylurea secretagogues target postprandial glycemia
64 Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus. A Randomized Controlled Trial. Yki-Jarvinen et al. Ann Intern Med 1999;130: Methods. Enrolled pts with fasting glu > 144 mg/dl, and > 3 yrs sulfonylurea therapy Randomized to bedtime NPH plus glyburide, metformin, or AM NPH
65 Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus. A Randomized Controlled Trial. Yki-Jarvinen et al. Ann Intern Med 1999;130: Results. Best control in combination metformin and bedtime NPH group (9.7% A1c baseline, 7.2% A1c at 1 yr) No weight gain in metformin and bedtime NPH group; 4 kg at 1 yr. in other groups Less symptomatic and biochemical hypoglycemia in metformin and bedtime NPH group; 1.8 Vs episodes per pt per yr. in other groups
66 Yki-Jarvinen, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23: Type2 DM patients; age ~59 yrs, BMI Randomized to bedtime glargine Vs. bedtime NPH. Control and weight gain were the same at 1 year. Glargine lowered post-dinner glucose 9.9 Vs mmol/l (p < 0.02). Glargine induced less hypoglycemia 9.9% Vs. 24% (p < 0.02).
67 Rosenstock et al. Basal insulin therapy in type 2 diabetes. Diabetes Care 2001;24: patients randomized to qhs glargine Vs. NPH qhs or qam and qhs for 28 weeks, open label. Similar A1C improvements. 1 kg less wt gain (0.4 G Vs. 1.4 NPH ). Overall symptomatic hypoglycemia ~same (61% of pts receiving G Vs. 67% of pts receiving NPH ). Severe hypoglycemia (glu < 36 mg/dl) in 7% of pts receiving G Vs. 10% of pts receiving NPH (p=0.06). Nocturnal hypoglycemia reduced 25% (26.5% Vs. 35.5%; p = 0.01).
68 American Diabetes Association: Clinical Practice Recommendations Diabetes Care : Contains ADA practice guidelines. Available as full text at or via ADA website Includes guidelines for treatment of type 1 and type 2 diabetes, as well as multiple practical topics
69 American Diabetes Association. Insulin Administration. Diabetes Care 2004;26:S121-S124. Contains multiple tips about insulin: Don t mix glargine with other products When mixing rapid acting insulin and intermediate acting insulin, inject within 15 minutes Syringe reuse acceptable but needs meticulous attention to cleanliness; small needles (30 ga) develop barbed tips easily
A Case-based Approach to Treating Diabetes Workshop WF02. D.C. Dugdale MD University of Washington Dawn DeWitt MD University of Melbourne
A Case-based Approach to Treating Diabetes Workshop WF02 D.C. Dugdale MD University of Washington Dawn DeWitt MD University of Melbourne Conflicts of Interest Neither Dr. DeWitt nor Dr. Dugdale do paid
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationAPPENDIX American Diabetes Association. Published online at
APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationType 2 Diabetes Mellitus Insulin Therapy 2012
Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationInjecting Insulin into Out Patient Practice
Injecting Insulin into Out Patient Practice Kathleen Colleran, MD Associate Professor UNMHSC 4/22/10 Overview Natural history of Type 2 diabetes Reasons clinicians are reluctant to start insulin therapy
More informationBeyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM
Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationINSULIN THERAY دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد
INSULIN THERAY DIABETES1 IN TYPE دکتر رحیم وکیلی استاد غدد ومتابولیسم کودکان دانشگاه علوم پزشکی مشهد Goals of management Manage symptoms Prevent acute and late complications Improve quality of life Avoid
More informationImportant Stuff. Basal Bolus What Adjustments? Pt weighs 80kg
Diabetes Boot Camp Class 4 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Special Insulin and Pattern Management Diabetes Education Services 1998-2015. All rights
More informationGlycemic Control Insulin In The Hospital Setting
Glycemic Control Insulin In The Hospital Setting Glycemic Control The Evidence For Insulin s s Benefit The Mechanism of Insulin s s Benefit The Achievement of Insulin s s Benefit A Few Cases Hyperglycemia
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationTimely!Insulinization In!Type!2! Diabetes,!When!and!How
Timely!Insulinization In!Type!2! Diabetes,!When!and!How, FACP, FACE, CDE Professor of Internal Medicine UT Southwestern Medical Center Dallas, Texas Current Control and Targets 1 Treatment Guidelines for
More informationRhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain
Rhonda Eustice, PharmD, CDE Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Diabetes Management: The Three Legged Stool Diet Medication Exercise Objectives Know the treatment goals
More informationGuide to Starting and Adjusting Insulin for Type 2 Diabetes*
Guide to Starting and Adjusting Insulin for Type 2 Diabetes* www.cadth.ca * Adapted from Guide to Starting and Adjusting Insulin for Type 2 Diabetes, 2008 International Diabetes Center, Minneapolis, MN.
More informationMixed Insulins Pick Me
Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing
More informationMartin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine
The Approach to Inpatient Hyperglycemia Martin J Stevens MD, FRCP, Endocrinologist and Professor of Medicine Great Lakes Hospital Medical Symposium May 7th 2010 Further Increases in the Prevalence of Diabetes
More informationIn-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University
In-Hospital Management of Diabetes Dr Benjamin Schiff Assistant Professor McGill University No conflict of interest to declare CLINICAL SCENARIO 62 y/o male with hx of DM 2, COPD, and HT is admitted with
More informationTips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital
Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More informationMANAGEMENT OF TYPE 1 DIABETES MELLITUS
MANAGEMENT OF TYPE 1 DIABETES MELLITUS INVESTIGATIONS AND TREATMENT MANSI NAIK VII SEMESTER INVESTIGATIONS FASTING BLOOD SUGAR PLASMA GLUCOSE HEMOGLOBIN A 1c SYMPTOMS OF TYPE 1 DIABETES MELLITUS Polyuria
More informationStroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols. Askiel Bruno, MD, MS Protocol PI
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Treatment Protocols Askiel Bruno, MD, MS Protocol PI SHINE Synopsis Acute ischemic stroke
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationMedications for Diabetes
Medications for Diabetes Sweet, but not too sweet Colette Raymond, Pharm D June 15, 2011 Learning Objectives At the end of this presentation you should be able to: Understand the prevalence and types of
More informationInitiation and Titration of Insulin in Diabetes Mellitus Type 2
Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.
More informationEvolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk
Evolving insulin therapy: Insulin replacement methods and the impact on cardiometabolic risk Harvard/Joslin Primary Care Congress for Cardiometabolic Health 2013 Richard S. Beaser, MD Medical Executive
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationnocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded
Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,
More informationI. General Considerations
1 2 3 I. General Considerations A. Type I ( Juvenile Onset or IDDM) IDDM results from autoimmune destruction of beta cells inability to secrete insulin --> ketone formation --> DKA 4 Diabetic Ketoacidosis
More informationProviding Stability to an Unstable Disease
Basal Insulin Therapy Providing Stability to an Unstable Disease Thomas A. Hughes, M.D. Professor of Medicine - Retired Division of Endocrinology, Metabolism, and Diabetes University of Tennessee Health
More informationObjectives 2/13/2013. Figuring out the dose. Sub Optimal Glycemic Control: Moving to the Appropriate Treatment
Sub Optimal Glycemic Control: Moving to the Appropriate Treatment Judy Thomas, MSN, FNP-BC Holt and Walton, Rheumatology and Endocrinology Objectives Upon completion of this session you will be better
More informationNew Drug Evaluation: Insulin degludec/aspart, subcutaneous injection
New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand
More informationComparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary
Number 14 Effective Health Care Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes Executive Summary Background and Key Questions
More informationSpecial Situations 1
Special Situations 1 Outline Continuous Nutrition Tube feeds TPN Steroids Pumps Perioperative BG Control 2 Patient receiving continuous TF or TPN Continuous nutrition coverage options: Analog q4hr Regular
More informationInpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin
Inpatient Diabetes Management: The Slippery Slope of Sliding Scale Insulin David Newman, MD University of North Dakota School of Medicine Sanford Health Big Sky Conference 2017 Dr. David Newman, Personal/Professional
More informationType I Type II Insulin Resistance
Insulin An aqueous hormonal solution made in the pancreas. Affects metabolism by allowing glucose to leave the blood and enter the body cells, preventing hyperglycemia. It is measured in units, e.g. 100
More informationDiabetes Related Disclosures
Diabetes Related Disclosures Speakers Bureau Amylin Boehringer Ingelheim Eli Lilly Takeda Classification of Diabetes Diabetes Care January 2011 vol. 34 no. Supplement 1 S11-S61 Type 1 Diabetes Mellitus
More informationDisclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2
Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director
More informationPHARMACISTS INTERACTIVE EDUCATION CASE STUDIES
PHARMACISTS INTERACTIVE EDUCATION CASE STUDIES Disclaimer: The information in this document is not a substitute for clinical judgment in the care of a particular patient. CADTH is not liable for any damages
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationΑναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς
Αναγκαιότητα και τρόπος ρύθμισης του διαβήτη στους νοσηλευόμενους ασθενείς Αναστασία Θανοπούλου Επίκουρη Καθηγήτρια Β Παθολογικής Κλινικής Πανεπιστημίου Αθηνών Διαβητολογικό Κέντρο, Ιπποκράτειο Νοσοκομείο
More informationInpatient Glycemic Management:
Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationDiabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical
Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)
More informationSponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationADVANCE Endpoints. Primary outcome. Secondary outcomes
ADVANCE Trial-NEJM 11,140 type 2 patients with h/o microvascular or macrovascular disease or 1 vascular disease risk factor Control A1c to 6.5% vs standard tx Intensive arm received gliclazide XL 30 to
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationManagement: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018
Management: How Can We Do Better? Lori B. Sweeney, MD 2018 Virginia ACP Clinical Update March 17, 2018 Disclosures I have no Objectives Use a case-based format to discuss diabetes management pearls Discuss
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationPoll Question 2. Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services.
Special Boot Camp Workshop Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Poll Question 1 Mary takes 6 units lispro (Humalog) before dinner. Which BG result reflects
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationDiabetes Basics. Type 1 diabetes The body cannot make insulin Requires insulin injection Is not treated with oral diabetes medicines (pills)
Diabetes Basics What is Diabetes? Diabetes is a disease in which the pancreas is unable to make insulin or the body is unable to use insulin or both. This leads to high blood sugar levels in the blood.
More informationUKPDS: Over Time, Need for Exogenous Insulin Increases
UKPDS: Over Time, Need for Exogenous Insulin Increases Patients Requiring Additional Insulin (%) 60 40 20 Oral agents By 6 Chlorpropamide years, Glyburide more than 50% of UKPDS patients required insulin
More informationPosition Statement of ADA / EASD 2012
Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations
More informationTransition of Care in Hospitalized Patients with Hyperglycemia and Diabetes
Transition of Care in Hospitalized Patients with Hyperglycemia and Diabetes Critically ill patients in the ICU Hospital Non-ICU Settings Home Guillermo E Umpierrez, MD, FACP, FACE Professor of Medicine
More informationInsulin Basics. Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology
Insulin Basics Bryan Primary Care Conference May 21, 2016 Shannon Wakeley MD Complete Endocrinology Disclosures Speakers Bureau for Sanofi, Astra Zeneca, Janssen, Boehringer-Ingelheim Objectives Discuss
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationHypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??
Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider
More informationThis certificate-level program is non-sponsored.
Program Name: Diabetes Education : A Comprehensive Review Module 5 Intensive Insulin Therapy Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationINSULIN 101: When, How and What
INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form
More informationDiabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016
Diabetes Mellitus Raja Nursing Instructor 09/03/2016 Acknowledgement: Badil Objective: Define Diabetes Mellitus (DM) & types of DM. Understand the pathophysiology of Type-I & II DM. List the clinical features
More informationInpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy
Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationUpdate on Insulin-based Agents for T2D. Harry Jiménez MD, FACE
Update on Insulin-based Agents for T2D Harry Jiménez MD, FACE Harry Jiménez MD, FACE Has received honorarium as Speaker and/or Consultant for the following pharmaceutical companies: Eli Lilly Merck Boehringer
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationThursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts
Thursday School 2010 Management of Inpatient Diabetes and Hyperglycemia and Quality Improvement Efforts Kendall Rogers, MD Using subcutaneous insulin to reliably achieve desired glycemic outcomes in non-critically
More informationManagement of Diabetes New Concepts New Devices New Medications. Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth
Management of Diabetes New Concepts New Devices New Medications Richard J. Comi, MD Professor of Medicine Geisel School of Medicine at Dartmouth Objectives: At the end of this lecture, the learner will
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationUsing Insulin in the Primary Care Setting: Interactive Cases
Using Insulin in the Primary Care Setting: Interactive Cases Irl B. Hirsch, MD University of Washington School of Medicine Dualities (Nov, 2011) Research Grants: sanofi-aventis, Novo Nordisk, Halozyme,
More informationReview of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
REVIEW Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes Nazia Raja-Khan Sarah S Warehime Robert A Gabbay Division of Endocrinology, Diabetes, and Metabolism, Penn State Institute
More informationBEST 4 Diabetes. Optimisation of insulin module
BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose
More informationJanuary 7, 5:00 p.m. EST
Study 3-151 Phase 2 Trial: Preliminary Results BIOD-531, a Concentrated Ultra-Rapid-Acting Prandial/Basal Insulin, Demonstrates Superior Post-Meal Glucose Control Compared to Marketed Prandial/Basal Insulins
More informationHanyang University Guri Hospital Chang Beom Lee
Hanyang University Guri Hospital Chang Beom Lee Meal prayer, Van Brekelenkam 17 th C Introduction 2012 ADA/EASD Position Statement Proper Patients for Pioglitazone β-cell Preservation by Pioglitazone Benefit
More informationDEMYSTIFYING INSULIN THERAPY
DEMYSTIFYING INSULIN THERAPY ASHLYN SMITH, PA-C ENDOCRINOLOGY ASSOCIATES SCOTTSDALE, AZ SECRETARY, AMERICAN SOCIETY OF ENDOCRINE PHYSICIAN ASSISTANTS ARIZONA STATE ASSOCIATION OF PHYSICIAN ASSISTANTS SPRING
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More information5/16/2018. Insulin Update: New and Emerging Insulins. Disclosures to Participants. Learning Objectives
Insulin Update: New and Emerging Insulins Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA Disclosures to
More informationManaging Diabetes for Improved Health and Economic Outcomes
Managing Diabetes for Improved Health and Economic Outcomes Based on a presentation by David McCulloch, MD Presentation Summary The contribution of postprandial glucose to diabetes progression and diabetes-related
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationInsulin Regimens: Hitting Glycemia Targets
Insulin Regimens: Hitting Glycemia Targets Grant Kelley MD March 1 st, 2018 Faculty Disclosure: Financial relationships with commercial interests None Overview Mortality and Morbidity Insulin and Insulin
More informationInsulin Prior Authorization with optional Quantity Limit Program Summary
Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)
More informationNew Therapies for Diabetes Management: Hope or Headache?
New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More information9/16/2013. No Conflict of Interest to Disclose
Catie Prinzing MSN, APRN, Clinical Nurse Specialist September 27, 2013 No Conflict of Interest to Disclose List key concepts to determining patient insulin doses during transitions in care Identify 5 points
More informationStarting and Helping People with Type 2 Diabetes on Insulin
Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants
More informationINSULIN THERAPY. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital
INSULIN THERAPY Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 3 Sep. 2013 Case Somsak is a 64-year-old man was diagnosed with T2DM, HT, and dyslipidemia 9 years ago. No history of hypoglycemia
More informationBasal Bolus Insulin Therapy Frequently Asked Questions
1. What is Basal Bolus Insulin Therapy (BBIT)? 2. What evidence supports the use of subcutaneous Basal Bolus Insulin Therapy? 3. Does Basal Bolus Insulin Therapy apply to all patients? 4. What s wrong
More informationWhat s the Goal? Individualizing Glycemic Targets. Matthew Freeby M.D. December 3 rd, 2016
What s the Goal? Individualizing Glycemic Targets Matthew Freeby M.D. December 3 rd, 2016 Diabetes Mellitus: Complications and Co-Morbid Conditions Retinopathy Between 2005-2008, 28.5% of patients with
More informationBasics of Continuous Subcutaneous Insulin Infusion Therapy. Lubna Mirza, MD Norman Endocrinology Associates 2018
Basics of Continuous Subcutaneous Insulin Infusion Therapy Lubna Mirza, MD Norman Endocrinology Associates 2018 Preamble Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients
More informationYour Chart Review Data. Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine
Your Chart Review Data Lara Zisblatt, MA Assistant Director Continuing Medical Education Boston University School of Medicine Participation 243 registered for the program 98 have completed the Practice
More information